Hematology / Oncology | Emory School of Medicine

The Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and the Emory University School of Medicine celebrated its 30^th anniversary in 2025. We are one of the largest programs of our kind in the country, and our center is at the forefront of the field of pediatric hematology, oncology and blood and marrow transplant. We are the pediatric component of the Winship Cancer Institute of Emory University, the first and only comprehensive National Cancer Institute (NCI)-designated cancer institute in Georgia. Our center has grown to more than 130 faculty members, more than a seven-fold increase since its establishment and nearly double our size just a decade ago.

We are excited to share some highlights of our center:

A strong partnership with Aflac Inc., with nearly $200M in contributions to research efforts.
A Cell and Gene Therapeutics Program focused on the development and implementation of novel gene therapy for the treatment of childhood cancers and bleeding disorders, including leadership of the Marcus Center for Cell & Gene Therapy and GMP Lab at Children’s Healthcare of Atlanta.
Comprehensive genetic counseling and surveillance for children who are at risk for developing cancer due to a cancer predisposition syndrome, family history of cancer or diagnosis of a rare type of cancer through our Cancer Predisposition Program.
A Cancer Precision Medicine Program that treats high risk or refractory cancer patients through genomic profiling of high-risk tumors.
A High-Risk Leukemia and Lymphoma Program that is one of only a handful of similar collaborative programs in the nation.
We are the pediatric component of the Winship Cancer Institute of Emory University, the first and only comprehensive National Cancer Institute (NCI)-designated cancer institute in Georgia.
One of the largest Immunohematology Dysregulation Programs in the country.
Building one of the nation’s premier programs in Epidemiology and Population Sciences.
Members of the Georgia Solve Sickle Cell Initiative, a $16M investment to advance knowledge, treatment and potential cures for sickle cell disease.
Over 290 clinical studies open to enrollment with 30 of those being investigator-initiated trials.
We generated direct costs of more than $31.1M in 2024 in extramural research funding, including more than $17M from the National Institutes of Health (NIH).

We are very grateful for the collaborative relationships we have with other pediatric hematologists and oncologists nationwide.

For more information, please visit here.

Douglas K. Graham, MD, PhD
Professor of Pediatrics
William G. Woods Chair
Chief, Aflac Cancer & Blood Disorders Center
Children’s Healthcare of Atlanta
Division Chief, Pediatric Hematology/Oncology/BMT
Emory University School of Medicine